Anja Health vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Affordable cord blood and tissue banking with FDA-registered storage for broader stem cell access; $4.62M from Seven Seven Six and YC at $1.8M revenue competing with CBR for expectant parent insurance market.
About
Anja Health is a San Jose-based cord blood and cord tissue banking company that makes stem cell preservation from newborn births accessible and affordable — providing nationwide FDA-registered collection and storage of umbilical cord blood and cord tissue that contain hematopoietic stem cells and mesenchymal stem cells, which may be used in future treatments for blood disorders, immune conditions, and emerging regenerative medicine applications. Founded in 2021 and backed by Alexis Ohanian's Seven Seven Six fund and Y Combinator with $4.62 million raised including a $2 million seed round in May 2024, Anja Health achieved $1.8 million in revenue as of December 2024.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.